Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProBio platform trial in metastatic prostate cancer
2023-506857-40-00Phase 3Authorised
- Sponsor
- Karolinska Institutet
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of darolutamide, cabazitaxel, radium-223 dichloride, abiraterone, niraparib and 5 more in prostate cancer (PCa), sponsored by Karolinska Institutet. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: authorised.
02
Drugs
darolutamidecabazitaxelradium-223 dichlorideabirateroneniraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-506857-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506857-40-00.